Renalytix plc
("Renalytix" or the "Company")
Directorate Change
LONDON and SALT LAKE CITY - December 8, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that Dr Chirag Parikh has stepped down from his role as independent Non-Executive Director of Renalytix with immediate effect.
The Company will seek to recruit a new independent Non-Executive Director and will provide an update in due course.
The Ordinary Resolution to re-appoint Dr Parikh to the Board of Directors will be withdrawn for the Annual General Meeting to be held on 15 December 2023.
For further information, please contact:
Renalytix plc | |
James McCullough, CEO | Via Walbrook PR |
|
|
Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 |
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea |
|
|
|
Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 |
Gary Clarence / Shalin Bhamra |
|
| |
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com |
Paul McManus / Alice Woodings | Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
| |
CapComm Partners | |
Peter DeNardo | Tel: 415-389-6400 or investors@renalytix.com |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.